Person:
YUMUK, PERRAN FULDEN

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

YUMUK

First Name

PERRAN FULDEN

Name

Filters

2003 - 20074
Reset filters

Settings

End date: 2009 × Subject: CANCER ×

Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    PublicationOpen Access
    D-dimer - Can it be a marker for malignant gastric lesions?
    (TAYLOR & FRANCIS LTD, 2004-12) YUMUK, PERRAN FULDEN; Aliustaoglu, M; Yumuk, PF; Gumus, M; Ekenel, M; Bolukbas, F; Bolukbas, C; Mutlu, N; Basaran, G; Avsar, E; Turhal, NS
  • No Thumbnail Available
    PublicationMetadata only
    Vascular endothelial growth factor, hypoxia-inducible factor 1 alpha and CD34 expressions in early-stage gastric tumors: Relationship with pathological factors and prognostic impact on survival
    (KARGER, 2007) ÇELİKEL, ÇİĞDEM; Cabuk, Devrim; Basaran, Gul; Celikel, Cigdem; Dane, Faysal; Yumuk, P. Fulden; Iyikesici, M. Salih; Ekenel, Meltem; Turhal, N. Serdar
    Background: Angiogenesis is one of the key steps in solid tumor growth and metastasis. We planned to investigate the prognostic significance of vascular endothelial growth factor (VEGF), hypoxia-inducible factor 1 alpha (HIF-1 alpha) and CD34 expressions as markers of angiogenesis in gastric cancer. Patients and Methods: We retrospectively reviewed the medical records of 51 gastric cancer patients who had total or subtotal gastrectomy at Marmara University Hospital from 1990 to 2004 and evaluated the expression of VEGF, HIF-1 alpha and CD34 by immunohistochemistry in their archival tumor tissues. We recorded the clinical and pathological characteristics of these patients and analyzed their survival outcome. Results: Thirty out of 51 patients were males. The median age was 63 years (range 34-81). The median follow-up was 17 months. Thirty-six patients had node-positive disease. The majority of patients (n = 43) had T2 and T3 disease. Vascular and lymphatic invasions were present in 57 and 77% of tumors, respectively. VEGF and HIF-1 alpha were positive in 65 and 71% of tumors. The median CD34 staining score was 19 (3-68). VEGF, HIF-1 alpha and CD34 expressions were more frequent in tumors without serosal invasion (p = 0.01, p = 0.01 and p = 0.003, respectively). CD34 expression was significantly more frequent in tumors with VEGF and HIF-1 alpha expression (p = 0.00, p = 0.00). HIF-1 alpha expression was more frequent in tumors with VEGF expression (p = 0.00). The 5year overall survival was 45%. VEGF, HIF-1 alpha, CD34 expressions and other pathological characteristics were found to have no impact on survival. Conclusion: VEGF, HIF-1 alpha and CD34 expressions were more common in tumors without serosal invasion. As a future perspective, biological agents targeting VEGF and HIF-1 alpha might be more effective at earlier stages of gastric cancer. Copyright (c) 2007 S. Karger AG, Basel.
  • No Thumbnail Available
    PublicationMetadata only
    Limited painful mouth opening
    (W B SAUNDERS CO, 2005) YUMUK, PERRAN FULDEN; Guler, N; Yumuk, PF; Ilguy, D; Gac, V; Greer, J
  • No Thumbnail Available
    PublicationMetadata only
    Outcome of rectal and sigmoid carcinoma patients receiving adjuvant chemoradiotherapy in marmara university hospital
    (TAYLOR & FRANCIS LTD, 2003) YUMUK, PERRAN FULDEN; Yumuk, PF; Abacioglu, U; Caglar, H; Gumus, M; Sengoz, M; Turhal, NS
    Adjuvant chemoradiotherapy is the standard treatment in resected stage II/III rectosigmoid carcinoma. We report a retrospective analysis of 33 patients who received adjuvant chemoradiotherapy. Patients received 5-fluorouracil (375mg/m(2)/day x 5days) and calcium leucovorin (20mg/m(2)/day x 5days), q4weeks, two courses before and two courses after radiotherapy. The 5-fluorouracil dose was reduced to 225mg/m(2)/day given continuously as protracted short-term infusion on the first and last 3 days during radiotherapy. Radiotherapy was started at 7th week and 45-50.4 Gy was given to pelvic region. Median age was 63 years. Median follow-up was 38 months starting from the operation date. Four-year local and distant control rates were 78% and 69%, respectively. Four-year disease-free survival and overall survival were 60% and 62%, respectively. Protracted short-term infusion of 5-fluorouracil during pelvic irradiation is a safe treatment modality. Further studies are needed to improve the local control of high-risk rectal and sigmoid carcinomas.